

A New Physio-Anatomic Brain Map



Luisetto M^{1*} and Behzad Nili-Ahmadabadi²

¹Applied pharmacologist, European Specialist in Lab Medicine, Italy

²Independent researcher, USA

Submission: September 27, 2017; **Published:** November 22, 2017

***Corresponding author:** Luisetto M, Applied Pharmacologist, European Specialist in Lab Medicine, Italy, Email: Mauro65@gmail.com

Keywords: Brain maps; Neuroscience; Emotional systems

Introduction

We have seen in the last 2 centuries different ways to have a brain map using various strategies. Since from BROADMAN theories we have seen the introducing of technologies to support these working methods. (old and new) as EEG, TC, PET, FMRI, MEG, NIRS and others with the scope to differentiate brain areas in order to show their specific activity.

This has made possible to produce an anatomic image and map about the different brain areas to be related with some different functions or dysfunctions. But what we can think is to create a new anatomic brain map using the drugs and substances that show high activity levels in the neurology field [1].

In example a new pharmacology brain map can be obtained using different molecules or physiopathological conditions:

- A. BDZ GABA receptor, Barbiturate, Opioids, Neuroleptics, Antiepileptics, Antidepressives, Hypnotics
- B. Anti migraine, Amfetaminic, Anti Parkinson, Antidementia, Antimuscarinics, Anticholinergics
- C. Analgesics, General anaesthetics, Antistaminics, Poisons and Toxins, Antipyretics, Antihypertensives
- D. Addiction substances, Ethanol, Nicotine, New smart drugs, Heavy metals
- E. Vegetal substances, Cannabinoids, Oxygen and CO₂, Toxic substances (as cyanide), insulin
- F. Food (involved in Leptin metabolism), carbohydrates level, metabolic toxic subst. MABS and many other drugs and substances or physiopathological conditions.

This map must be created adding the single signal in a complex design in order to achieve a different point of view in neurosciences. We can also see that some brain condition (as EMOTIONAL STATUS)

are not covered today by drugs registered for this indication (by pharmaceutical industries) and these conditions need a deeply research about the real reason [2].

In our opinion can be relevant is to verify the function of some brain areas and systems not covered by drugs other pharmacological substances effect. Why many areas and brain systems are interested by pharmaceutical industry activity and others not? This approach can be useful in some fields as forensic science, jurisdictional settings, HR management, and many others (Emotional Systems).

Discussion and Conclusion

Under the light of this consideration we submit to scientific community a new method to create an anatomical brain map to be associated to the existing methods [3].

Every substance or drug (or condition) we have seen interact with a specific area or system and we can easily conjugate with radioactive or other molecular tracers to detect which imaging the specific area involved. The same using other physical or neuro active molecules or physiologic-pathologic conditions. We can think to add this approach with the other existing today to have a more interesting brain physio-anatomic schema.

Is not a new procedure but we think is innovative is to create a complex map using this information. (What cells involved and related intensity of signal and objective effect). Information that comes directly from the cell or systems involved. We can have a physiology and anatomic information complete related with the efficacy of some drugs or substances [4].

This approach starts from observing some brain disease (or systemic) and the effect due by some iatrogenic or toxic substances and the drugs (used in therapy). To a pathology is related a system of neurons dysfunctions (or other noxa) and an efficacy drug link to this or modulate them. Observing in a complex way all

this evidence we can have an global new image of brain physio-anatomy.

We have written this paper observing that in some brain condition until today we don't have registered drugs (in example in field of emotional system) and with the scope to give a more objective way in pharmacological molecule evaluation (effect objectively verified by instrumental or physical-bio chemistry methods).

Clarification

This Short Communication has not any diagnostic or therapeutic intent, only written in order to Produce research hypothesis.



This work is licensed under Creative Commons Attribution 4.0 License
DOI: [10.19080/JOJS.2019.02.555594](https://doi.org/10.19080/JOJS.2019.02.555594)

References

1. Luisetto M, Farhan AK, Cabianca L, Mokbul MI, Yesvi Rafa A, et al. (2016) Amygdale pharmacology and crime behavior, dysfunctions to be considered as a disease? IABCR International Archives of Biomedical and Clinical Research 2(2): 1-4.
2. Luisetto M (2017) Brain and transmission signal modulation. Theranostics Brain,Spine & Neural Disord 1(1): 1.
3. Luisetto M (2017) Attitudes and skills in business working settings: A HR management tool. Business and economics journal 8: 1.
4. Luisetto M (2017) The Economic costs of some preventable brain disorder. Theranostics Brain,Spine & Neural Disord 1(4): 1.

Your next submission with Juniper Publishers will reach you the below assets

- Quality Editorial service
- Swift Peer Review
- Reprints availability
- E-prints Service
- Manuscript Podcast for convenient understanding
- Global attainment for your research
- Manuscript accessibility in different formats
(Pdf, E-pub, Full Text, Audio)
- Unceasing customer service

Track the below URL for one-step submission
<https://juniperpublishers.com/online-submission.php>